Segall Bryant & Hamill LLC Has $453,000 Stock Holdings in Bioventus Inc. (NYSE:BVS)

Segall Bryant & Hamill LLC decreased its position in Bioventus Inc. (NYSE:BVS - Free Report) by 85.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 49,547 shares of the company's stock after selling 303,082 shares during the quarter. Segall Bryant & Hamill LLC owned 0.06% of Bioventus worth $453,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in BVS. Allspring Global Investments Holdings LLC grew its holdings in Bioventus by 54.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 36,829 shares of the company's stock worth $337,000 after acquiring an additional 12,915 shares during the period. Harbor Capital Advisors Inc. bought a new position in Bioventus in the 1st quarter worth approximately $200,000. Summit Global Investments increased its position in shares of Bioventus by 3.9% during the first quarter. Summit Global Investments now owns 54,752 shares of the company's stock valued at $501,000 after purchasing an additional 2,077 shares during the period. GAMMA Investing LLC increased its position in shares of Bioventus by 3,228.7% during the first quarter. GAMMA Investing LLC now owns 5,792 shares of the company's stock valued at $53,000 after purchasing an additional 5,618 shares during the period. Finally, California State Teachers Retirement System lifted its holdings in shares of Bioventus by 1,138.9% during the fourth quarter. California State Teachers Retirement System now owns 33,697 shares of the company's stock valued at $354,000 after acquiring an additional 30,977 shares during the period. 62.94% of the stock is currently owned by hedge funds and other institutional investors.

Bioventus Price Performance

Shares of BVS traded up $0.04 during mid-day trading on Monday, hitting $6.30. 238,071 shares of the company were exchanged, compared to its average volume of 429,754. The company has a 50 day moving average of $6.69 and a 200-day moving average of $8.33. Bioventus Inc. has a 1-year low of $6.02 and a 1-year high of $14.38. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41. The stock has a market cap of $517.51 million, a price-to-earnings ratio of -10.33 and a beta of 0.84.

Analyst Ratings Changes

BVS has been the subject of several research analyst reports. Cantor Fitzgerald initiated coverage on Bioventus in a research note on Monday, July 7th. They set an "overweight" rating and a $12.00 target price for the company. Craig Hallum set a $15.00 price objective on Bioventus and gave the stock a "buy" rating in a research report on Wednesday, May 7th.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.